6320 Quadrangle Drive
United States - Map
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.
|Cempra, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 9; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Prabhavathi B. Fernandes Ph.D.,
Founder, Chief Exec. Officer, Pres and Director
|Mr. Mark W. Hahn ,
Chief Financial Officer and Exec. VP
|Mr. Shane Barton ,
Chief Accounting Officer, Sec. and Controller
|Mr. Kenneth Eheman Jr.,
|Mr. Carl T. Foster ,
Exec. VP of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|